These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17515370)

  • 21. Musculoskeletal tumors: use of proton MR spectroscopic imaging for characterization.
    Fayad LM; Bluemke DA; McCarthy EF; Weber KL; Barker PB; Jacobs MA
    J Magn Reson Imaging; 2006 Jan; 23(1):23-8. PubMed ID: 16315208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy.
    Bartella L; Thakur SB; Morris EA; Dershaw DD; Huang W; Chough E; Cruz MC; Liberman L
    Radiology; 2007 Oct; 245(1):80-7. PubMed ID: 17885182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human breast lesions: characterization with proton MR spectroscopy.
    Roebuck JR; Cecil KM; Schnall MD; Lenkinski RE
    Radiology; 1998 Oct; 209(1):269-75. PubMed ID: 9769842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1H MR spectroscopy of invasive ductal carcinoma: correlations with FDG PET and histologic prognostic factors.
    Tozaki M; Hoshi K
    AJR Am J Roentgenol; 2010 May; 194(5):1384-90. PubMed ID: 20410429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy--initial results.
    Yeung DK; Cheung HS; Tse GM
    Radiology; 2001 Jul; 220(1):40-6. PubMed ID: 11425970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three Tesla.
    Stanwell P; Russell P; Carter J; Pather S; Heintze S; Mountford C
    Invest Radiol; 2008 Oct; 43(10):745-51. PubMed ID: 18791417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Noninvasive evaluation of cerebral glioma grade by using multivoxel 3D proton MR spectroscopy.
    Zeng Q; Liu H; Zhang K; Li C; Zhou G
    Magn Reson Imaging; 2011 Jan; 29(1):25-31. PubMed ID: 20832225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-voxel proton brain spectroscopy exam (PROBE/SV) in patients with primary brain tumors.
    Tien RD; Lai PH; Smith JS; Lazeyras F
    AJR Am J Roentgenol; 1996 Jul; 167(1):201-9. PubMed ID: 8659372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 1H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration.
    Mahon MM; Williams AD; Soutter WP; Cox IJ; McIndoe GA; Coutts GA; Dina R; deSouza NM
    NMR Biomed; 2004 Feb; 17(1):1-9. PubMed ID: 15011245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Application value of 3T 1H-magnetic resonance spectroscopy in diagnosing tumors of bone and soft tissue].
    Qi ZH; Li CF; Ma XX; Li ZF; Zhang K; Yu DX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Oct; 33(5):504-10. PubMed ID: 22338133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of breast cancer using proton MR spectroscopy: total choline peak integral and signal-to-noise ratio as prognostic indicators.
    Shin HJ; Baek HM; Cha JH; Kim HH
    AJR Am J Roentgenol; 2012 May; 198(5):W488-97. PubMed ID: 22528931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ex vivo proton MR spectroscopy (1H-MRS) for evaluation of human gastric carcinoma.
    Mun CW; Cho JY; Shin WJ; Choi KS; Eun CK; Cha SS; Lee J; Yang YI; Nam SH; Kim J; Lee SY
    Magn Reson Imaging; 2004 Jul; 22(6):861-70. PubMed ID: 15234456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors.
    Spampinato MV; Smith JK; Kwock L; Ewend M; Grimme JD; Camacho DL; Castillo M
    AJR Am J Roentgenol; 2007 Jan; 188(1):204-12. PubMed ID: 17179366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical evaluation of choline measurement by proton MR spectroscopy in patients with malignant tumors.
    Lee J; Yamaguchi T; Abe A; Shizukuishi K; Uemura H; Miyagi E; Sakata K; Inoue T
    Radiat Med; 2004; 22(3):148-54. PubMed ID: 15287529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preliminary observations and diagnostic value of lipid peak in ovarian thecomas/fibrothecomas using in vivo proton MR spectroscopy at 3T.
    Takeuchi M; Matsuzaki K; Harada M
    J Magn Reson Imaging; 2012 Oct; 36(4):907-11. PubMed ID: 22585396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic changes in pelvic lesions: findings at proton MR spectroscopic imaging.
    Hascalik S; Celik O; Sarac K; Meydanli MM; Alkan A; Mizrak B
    Gynecol Obstet Invest; 2005; 60(3):121-7. PubMed ID: 15920339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1H MR spectroscopy and diffusion-weighted imaging of the breast: are they useful tools for characterizing breast lesions before biopsy?
    Tozaki M; Fukuma E
    AJR Am J Roentgenol; 2009 Sep; 193(3):840-9. PubMed ID: 19696300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MR Spectroscopy for Differentiating Benign From Malignant Solid Adnexal Tumors.
    Ma FH; Qiang JW; Cai SQ; Zhao SH; Zhang GF; Rao YM
    AJR Am J Roentgenol; 2015 Jun; 204(6):W724-30. PubMed ID: 26001263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo magnetic resonance spectroscopy of gynaecological tumours at 3.0 Tesla.
    Booth SJ; Pickles MD; Turnbull LW
    BJOG; 2009 Jan; 116(2):300-3. PubMed ID: 19076962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T.
    McLean MA; Priest AN; Joubert I; Lomas DJ; Kataoka MY; Earl H; Crawford R; Brenton JD; Griffiths JR; Sala E
    Magn Reson Med; 2009 Oct; 62(4):855-61. PubMed ID: 19645005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.